Clinical Research & Publications
Applied Biologics is committed to advancing the scientific understanding of amniotic membrane allografts through rigorous clinical investigation. We are dedicated to evidence-based medicine to validate the clinical benefits of our products for patients and healthcare providers.
Featured Research
Proprietary Processing of Placental Tissue Allografts Influences Wound Healing Trajectories in a Rodent Excisional Wound Model
Pilot rodent study sponsored by Applied Biologics finds that animals treated with a proprietary processed allograft showed more advanced progression toward wound resolution than those receiving the conventionally processed comparator.
Authors
Ashley Robertson, Taylor Carson & Joydeep Basu
For presentation at the Symposium on Advanced Wound Care (SAWC) Fall, October 15–18, 2026, Las Vegas, NV
Featured Ongoing Trial
Evaluating the Efficacy of XWRAP®, a Single Layer Placental-based Allograft, and Standard of Care Versus Standard of Care
We are currently sponsoring a multi-center randomized controlled clinical trial evaluating the efficacy of XWRAP® and standard of care versus standard of care alone in the management of nonhealing diabetic foot ulcers.
ClinicalTrials.gov ID
NCT06564831
Status
Recruiting
Study Start Date
September 2024
Estimated Completion
Fall 2026
Clinical Trials
A Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers (AB BIOH - DFU)
BIOxHEAL is an investigational biologic made from donated human amniotic membrane, placed directly on the wound to help it heal. Adults with type 1 or type 2 diabetes who have a foot ulcer that has not healed with standard wound care may be able to join. The main question is whether more ulcers close completely by Week 12 when BIOxHEAL is added to standard care.
Evaluating the Efficacy of XWRAP®, a Single Layer Placental-based Allograft, and Standard of Care Versus Standard of Care
We are currently sponsoring a multi-center randomized controlled clinical trial evaluating the efficacy of XWRAP® and standard of care versus standard of care alone in the management of nonhealing diabetic foot ulcers.
NCT ID
NCT06564831
Status
- Recruiting
Phase
Not Applicable
Est. Completion
Fall 2026
Publications
POSTER – Proprietary Processing of Placental Tissue Allografts Influences Wound Healing Trajectories in a Rodent Excisional Wound Model
Presented at the Symposium on Advanced Wound Care (SAWC) Fall, October 15–18, 2026, Las Vegas, NV
Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of the CAMPX Trial
Abstract written by Thomas Serena, MD; 2026
Evaluation of single layer amniotic membrane in the management of nonhealing diabetic foot ulcers: an interim analysis of CAMPX
International Journal of Tissue Repair, vol. 1, no. 1, Oct. 2025
https://doi.org/10.63676/m04r0s60
POSTER – Evaluation of single layer amniotic membrane in the management of nonhealing diabetic foot ulcers: an interim analysis of CAMPX
Poster published by Serena Group, 2025
Recurrent cubital tunnel syndrome treated with revision neurolysis and amniotic membrane nerve wrapping
Journal of Shoulder and Elbow Surgery, Oct 2016
https://doi.org/10.1016/j.jse.2016.09.013
XWRAP Human Amniotic Membrane in Combination with an Amniotic-Fluid-Derived Biologic Promotes Collagen Fibril Regeneration in a Preclinical Rabbit Model of Medial Collateral Ligament Injury
Preprint published in bioRxiv, Journal of Shoulder and Elbow Surgery, Sep 2026